MX2009007777A - Terapia de combinacion que comprende romidepsina y bortezomib. - Google Patents

Terapia de combinacion que comprende romidepsina y bortezomib.

Info

Publication number
MX2009007777A
MX2009007777A MX2009007777A MX2009007777A MX2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A MX 2009007777 A MX2009007777 A MX 2009007777A
Authority
MX
Mexico
Prior art keywords
romidepsin
bortezomib
proteasome inhibitor
combination therapy
cells
Prior art date
Application number
MX2009007777A
Other languages
English (en)
Inventor
Mitchell Keegan
Steven Grant
Original Assignee
Gloucester Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gloucester Pharmaceuticals Inc filed Critical Gloucester Pharmaceuticals Inc
Publication of MX2009007777A publication Critical patent/MX2009007777A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona una terapia de combinación para tratar cáncer y otros neoplasmas incluyendo romidepsina y un inhibidor de proteasomas. Cuando se administran juntos, la romidepsina y un inhibidor de proteasomas (por ejemplo, bortezomib) interactúan sinérgicamente para matar selectivamente células malignas a bajas (nanomolares) concentraciones. El efecto es particularmente pronunciado en células hematológicas malignas (por ejemplo, leucemia, linfoma, mieloma múltiple). La combinación también se ha encontrado útil para tratar cánceres resistentes a bortezomib y cánceres resistentes a esteroides. La invención proporciona métodos para matar células malignas in vitro e in vivo. Se proporcionan también composiciones farmacéuticas, preparaciones y kits que incluyen romidepsina y un inhibidor de proteasomas.
MX2009007777A 2007-01-23 2008-01-23 Terapia de combinacion que comprende romidepsina y bortezomib. MX2009007777A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88616907P 2007-01-23 2007-01-23
US577407P 2007-12-07 2007-12-07
PCT/US2008/000850 WO2008091620A2 (en) 2007-01-23 2008-01-23 Combination therapy comprising romidepsin and i.a. bortezomib

Publications (1)

Publication Number Publication Date
MX2009007777A true MX2009007777A (es) 2009-12-16

Family

ID=39323892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007777A MX2009007777A (es) 2007-01-23 2008-01-23 Terapia de combinacion que comprende romidepsina y bortezomib.

Country Status (8)

Country Link
US (1) US20090105200A1 (es)
EP (1) EP2117556A2 (es)
JP (1) JP2010516767A (es)
AU (1) AU2008209555A1 (es)
CA (1) CA2676387A1 (es)
IL (1) IL199992A0 (es)
MX (1) MX2009007777A (es)
WO (1) WO2008091620A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237621A (zh) 2005-11-09 2016-01-13 欧尼斯治疗公司 用于酶抑制的化合物
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
CN102458127B (zh) * 2009-05-27 2014-08-27 赛福伦公司 用于治疗多发性骨髓瘤的联合治疗
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
WO2023239821A2 (en) * 2022-06-07 2023-12-14 Lantern Pharma Inc. Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238982B8 (en) * 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
AU2007296259A1 (en) * 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors

Also Published As

Publication number Publication date
CA2676387A1 (en) 2008-07-31
US20090105200A1 (en) 2009-04-23
IL199992A0 (en) 2010-04-15
WO2008091620A3 (en) 2008-09-18
JP2010516767A (ja) 2010-05-20
WO2008091620A2 (en) 2008-07-31
EP2117556A2 (en) 2009-11-18
AU2008209555A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2009007777A (es) Terapia de combinacion que comprende romidepsina y bortezomib.
GB2430935A (en) Tetrapeptide analogs
SG164368A1 (en) Treatment of cancer
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
SI1742644T1 (sl) Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
HK1102991A1 (en) Pharmaceutical formulation of decitabine
TW200616615A (en) Compounds and methods for the treatment of cancer
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
HK1114338A1 (en) Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
GEP20125469B (en) Inhibitors of akt activity
MY161991A (en) Proteasome inhibitors
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
MX2007010996A (es) Nuevas composiciones de liposomas.
UA100852C2 (ru) Композиции для лечения рака
HK1093064A1 (en) Thienopyrimidine derivatives as potassium channel inhibitors
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
WO2007038868A3 (en) Novel enediyne compound and uses thereof
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal